Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations

被引：23

作者：

Abdel-Rahman, Omar ^{[1
]}

Lamarca, Angela ^{[2
]}

Valle, Juan W. ^{[2
,3
]}

Hubner, Richard A. ^{[2
]}

机构：

[1] Ain Shams Univ, Fac Med, Dept Clin Oncol, Cairo, Egypt

[2] Christie NHS Fdn Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England

[3] Univ Manchester, MAHSC, Manchester, Lancs, England

来源：

关键词：

hepatocellular carcinoma; somatostatin receptors; somatostatin analogues; octreotide; lanreotide; LONG-ACTING OCTREOTIDE; PHASE-III; RELEASE OCTREOTIDE; BREAST-CARCINOMA; HUMAN HEPATOMA; ANALOGS; CANCER; PROLIFERATION; MULTICENTER; PLACEBO;

D O I：

10.1530/ERC-14-0389

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Sorafenib is the only systemic therapy to demonstrate a significant survival benefit over supportive care in robust randomised controlled trials for advanced hepatocellular carcinoma (HCC). In the context of an intense search for prognostic and predictive factors for response and efficacy of different systemic therapies (including sorafenib), a number of molecular targets have been identified, paving new avenues for potential therapeutic opportunities. Such molecular targets include somatostatin receptor (SSTR)-related alterations. In this review, we provide an overview of the various considerations relating to SSTRs as potentially novel prognostic and predictive biomarkers for HCC with special emphasis on the therapeutic potential of somatostatin analogues in HCC management.

引用

页码：R485 / R493

页数：9

共 57 条

[1]

A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma [J].